Revolution Medicines reports Phase 1/1b data for RMC-6236 in NSCLC and PDAC; plans Phase 3 in 2024

Revolution Medicines, Inc.

RMC-6236 showed ORR 38% (DCR 85%) in evaluable NSCLC (n=40) and ORR 20% (DCR 87%) in PDAC (n=46) as of Oct 12, 2023.
Safety at ≥80 mg daily: mostly Grade 1-2 rash/GI events; one Grade 4 perforation led to discontinuation; no fatal TRAEs.
Company plans global randomized Phase 3 trial of RMC-6236 vs docetaxel in RAS-mutated NSCLC, aiming to start in 2024.
Potential Phase 3 vs physician's choice in PDAC and combo pivotal trials also planned, pending further data and regulatory feedback.
RMC-4630 combo with sotorasib showed additive toxicity without sufficient benefit; no further development for that combination.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.